Federal Circuit: Eye Syringe Claims From Novartis Are Unpatentable
WASHINGTON, D.C. — The U.S. Patent Trial and Appeal Board was correct to hold that a pharmaceutical company’s claims related to a prefilled syringe for eye diseases were unpatentable, a Federal...To view the full article, register now.
Already a subscriber? Click here to view full article